**Recent executive and agency actions have accelerated partial marijuana rescheduling while the timeline for broader changes remains tied to ongoing administrative proceedings.** In April 2026, following a December 2025 executive order directing expeditious review, the Department of Justice and DEA moved FDA-approved products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step addressed medical access and research priorities without resolving the full rescheduling of marijuana. An expedited DEA administrative hearing on broader Schedule III placement is now scheduled to begin June 29, 2026, replacing earlier proceedings and aiming to streamline the rulemaking process originally proposed in 2024. Trader assessments of completion dates reflect the hearing’s potential to set firm deadlines, any subsequent public comment periods or judicial review, and historical patterns of DEA scheduling actions, all of which introduce procedural uncertainty even under active administration support.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$764,577 ปริมาณ
Mar 31, 2026
June 30
2%
December 31
27%
$764,577 ปริมาณ
June 30
$340,717 ปริมาณ
2%
December 31
$158,977 ปริมาณ
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive and agency actions have accelerated partial marijuana rescheduling while the timeline for broader changes remains tied to ongoing administrative proceedings.** In April 2026, following a December 2025 executive order directing expeditious review, the Department of Justice and DEA moved FDA-approved products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step addressed medical access and research priorities without resolving the full rescheduling of marijuana. An expedited DEA administrative hearing on broader Schedule III placement is now scheduled to begin June 29, 2026, replacing earlier proceedings and aiming to streamline the rulemaking process originally proposed in 2024. Trader assessments of completion dates reflect the hearing’s potential to set firm deadlines, any subsequent public comment periods or judicial review, and historical patterns of DEA scheduling actions, all of which introduce procedural uncertainty even under active administration support.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$764,577วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive and agency actions have accelerated partial marijuana rescheduling while the timeline for broader changes remains tied to ongoing administrative proceedings.** In April 2026, following a December 2025 executive order directing expeditious review, the Department of Justice and DEA moved FDA-approved products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step addressed medical access and research priorities without resolving the full rescheduling of marijuana. An expedited DEA administrative hearing on broader Schedule III placement is now scheduled to begin June 29, 2026, replacing earlier proceedings and aiming to streamline the rulemaking process originally proposed in 2024. Trader assessments of completion dates reflect the hearing’s potential to set firm deadlines, any subsequent public comment periods or judicial review, and historical patterns of DEA scheduling actions, all of which introduce procedural uncertainty even under active administration support.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$764,577วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Recent executive and agency actions have accelerated partial marijuana rescheduling while the timeline for broader changes remains tied to ongoing administrative proceedings.** In April 2026, following a December 2025 executive order directing expeditious review, the Department of Justice and DEA moved FDA-approved products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step addressed medical access and research priorities without resolving the full rescheduling of marijuana. An expedited DEA administrative hearing on broader Schedule III placement is now scheduled to begin June 29, 2026, replacing earlier proceedings and aiming to streamline the rulemaking process originally proposed in 2024. Trader assessments of completion dates reflect the hearing’s potential to set firm deadlines, any subsequent public comment periods or judicial review, and historical patterns of DEA scheduling actions, all of which introduce procedural uncertainty even under active administration support.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย